Table 1. Patient's demographics, etiology, and clinical findings before and after IVBA.

Patients/Eye #	Lat	Age (years)	Gender	Duration of ME (months)	Etiology	ETDRS BCVA				OCT CMT				# of Injections
						Baseline	1 month	3 months	6 months	Baseline (μ)	1 month (μ)	3 months (μ)	6 months (μ)
1/1	OD	71	F	08	PMCE	20/125	20/63	20/63	20/63	239	245	280	283	1
1/2	OS	71	F	10	PMCE	20/63	20/63	20/80	20/80	233	250	272	273	1
2/3	OD	51	M	06	DME	20/80	20/40	20/40	20/40	505	308	320	321	2
2/4	OS	51	M	06	DME	CF	20/100	20/80	20/80	664	310	335	332	2
3/5	OS	69	M	02	CRVO	20/200	CF	CF	CF	502	510	516	520	4
4/6	OD	67	F	01	AMD	20/80	20/25	20/25	20/25	385	208	224	220	4
5/7	OD	82	M	07	AMD/BRVO	20/200	20/200	20/200	20/200	289	300	310	310	2

Abbreviations: AMD, exudative age-related macular degeneration; BCVA, best corrected visual acuity; BRVO, branch retinal vein occlusion; CMT, central macular thickness; CRVO, central retinal vein occlusion; DME, diabetic macular edema: ETDRS, Early Treatment Diabetic Retinopathy Study; F, female; IVBA, intravitreal bevacizumab and adalimumab; lat, laterality; M, male; ME, macular edema; OCT, optical coherence tomography; OD, right eye; #, number; OS, left eye; PMC, pseudophakic cystoid macular edema.